HIV Therapy involves taking a combination of HIV medicines . HIV Therapy is recommended for everyone who has HIV. HIV Therapy cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.
The global HIV Therapy market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for HIV Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for HIV Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for HIV Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of HIV Therapy include ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc., etc. In 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes:
This report presents an overview of global market for HIV Therapy, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of HIV Therapy, also provides the sales of main regions and countries. Highlights of the upcoming market potential for HIV Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the HIV Therapy sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global HIV Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for HIV Therapy sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc., etc.
By Company
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
Segment by Type
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of HIV Therapy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of HIV Therapy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Therapy sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 HIV Therapy Product Introduction
1.2 Market by Type
1.2.1 Global HIV Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Integrase Inhibitors
1.2.3 Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Combination HIV Medicines
1.2.5 Others
1.3 Market by Application
1.3.1 Global HIV Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global HIV Therapy Sales Estimates and Forecasts 2018-2029
2.2 Global HIV Therapy Revenue by Region
2.2.1 Global HIV Therapy Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global HIV Therapy Revenue by Region (2018-2023)
2.2.3 Global HIV Therapy Revenue by Region (2024-2029)
2.2.4 Global HIV Therapy Revenue Market Share by Region (2018-2029)
2.3 Global HIV Therapy Sales Estimates and Forecasts 2018-2029
2.4 Global HIV Therapy Sales by Region
2.4.1 Global HIV Therapy Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global HIV Therapy Sales by Region (2018-2023)
2.4.3 Global HIV Therapy Sales by Region (2024-2029)
2.4.4 Global HIV Therapy Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global HIV Therapy Sales by Manufacturers
3.1.1 Global HIV Therapy Sales by Manufacturers (2018-2023)
3.1.2 Global HIV Therapy Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of HIV Therapy in 2022
3.2 Global HIV Therapy Revenue by Manufacturers
3.2.1 Global HIV Therapy Revenue by Manufacturers (2018-2023)
3.2.2 Global HIV Therapy Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by HIV Therapy Revenue in 2022
3.3 Global Key Players of HIV Therapy, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global HIV Therapy Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global HIV Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of HIV Therapy, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of HIV Therapy, Product Offered and Application
3.8 Global Key Manufacturers of HIV Therapy, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global HIV Therapy Sales by Type
4.1.1 Global HIV Therapy Historical Sales by Type (2018-2023)
4.1.2 Global HIV Therapy Forecasted Sales by Type (2024-2029)
4.1.3 Global HIV Therapy Sales Market Share by Type (2018-2029)
4.2 Global HIV Therapy Revenue by Type
4.2.1 Global HIV Therapy Historical Revenue by Type (2018-2023)
4.2.2 Global HIV Therapy Forecasted Revenue by Type (2024-2029)
4.2.3 Global HIV Therapy Revenue Market Share by Type (2018-2029)
4.3 Global HIV Therapy Price by Type
4.3.1 Global HIV Therapy Price by Type (2018-2023)
4.3.2 Global HIV Therapy Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global HIV Therapy Sales by Application
5.1.1 Global HIV Therapy Historical Sales by Application (2018-2023)
5.1.2 Global HIV Therapy Forecasted Sales by Application (2024-2029)
5.1.3 Global HIV Therapy Sales Market Share by Application (2018-2029)
5.2 Global HIV Therapy Revenue by Application
5.2.1 Global HIV Therapy Historical Revenue by Application (2018-2023)
5.2.2 Global HIV Therapy Forecasted Revenue by Application (2024-2029)
5.2.3 Global HIV Therapy Revenue Market Share by Application (2018-2029)
5.3 Global HIV Therapy Price by Application
5.3.1 Global HIV Therapy Price by Application (2018-2023)
5.3.2 Global HIV Therapy Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada HIV Therapy Market Size by Type
6.1.1 US & Canada HIV Therapy Sales by Type (2018-2029)
6.1.2 US & Canada HIV Therapy Revenue by Type (2018-2029)
6.2 US & Canada HIV Therapy Market Size by Application
6.2.1 US & Canada HIV Therapy Sales by Application (2018-2029)
6.2.2 US & Canada HIV Therapy Revenue by Application (2018-2029)
6.3 US & Canada HIV Therapy Market Size by Country
6.3.1 US & Canada HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada HIV Therapy Sales by Country (2018-2029)
6.3.3 US & Canada HIV Therapy Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe HIV Therapy Market Size by Type
7.1.1 Europe HIV Therapy Sales by Type (2018-2029)
7.1.2 Europe HIV Therapy Revenue by Type (2018-2029)
7.2 Europe HIV Therapy Market Size by Application
7.2.1 Europe HIV Therapy Sales by Application (2018-2029)
7.2.2 Europe HIV Therapy Revenue by Application (2018-2029)
7.3 Europe HIV Therapy Market Size by Country
7.3.1 Europe HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe HIV Therapy Sales by Country (2018-2029)
7.3.3 Europe HIV Therapy Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China HIV Therapy Market Size
8.1.1 China HIV Therapy Sales (2018-2029)
8.1.2 China HIV Therapy Revenue (2018-2029)
8.2 China HIV Therapy Market Size by Application
8.2.1 China HIV Therapy Sales by Application (2018-2029)
8.2.2 China HIV Therapy Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia HIV Therapy Market Size by Type
9.1.1 Asia HIV Therapy Sales by Type (2018-2029)
9.1.2 Asia HIV Therapy Revenue by Type (2018-2029)
9.2 Asia HIV Therapy Market Size by Application
9.2.1 Asia HIV Therapy Sales by Application (2018-2029)
9.2.2 Asia HIV Therapy Revenue by Application (2018-2029)
9.3 Asia HIV Therapy Sales by Region
9.3.1 Asia HIV Therapy Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia HIV Therapy Revenue by Region (2018-2029)
9.3.3 Asia HIV Therapy Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America HIV Therapy Market Size by Type
10.1.1 Middle East, Africa and Latin America HIV Therapy Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America HIV Therapy Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America HIV Therapy Market Size by Application
10.2.1 Middle East, Africa and Latin America HIV Therapy Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America HIV Therapy Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America HIV Therapy Sales by Country
10.3.1 Middle East, Africa and Latin America HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America HIV Therapy Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America HIV Therapy Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Company Information
11.1.2 ViiV Healthcare Overview
11.1.3 ViiV Healthcare HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 ViiV Healthcare HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 ViiV Healthcare Recent Developments
11.2 Gilead Sciences, Inc.
11.2.1 Gilead Sciences, Inc. Company Information
11.2.2 Gilead Sciences, Inc. Overview
11.2.3 Gilead Sciences, Inc. HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Gilead Sciences, Inc. HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Gilead Sciences, Inc. Recent Developments
11.3 GlaxoSmithKline Plc
11.3.1 GlaxoSmithKline Plc Company Information
11.3.2 GlaxoSmithKline Plc Overview
11.3.3 GlaxoSmithKline Plc HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 GlaxoSmithKline Plc HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GlaxoSmithKline Plc Recent Developments
11.4 Merck Sharp & Dohme Corp.
11.4.1 Merck Sharp & Dohme Corp. Company Information
11.4.2 Merck Sharp & Dohme Corp. Overview
11.4.3 Merck Sharp & Dohme Corp. HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Merck Sharp & Dohme Corp. HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck Sharp & Dohme Corp. Recent Developments
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Information
11.5.2 Bristol-Myers Squibb Company Overview
11.5.3 Bristol-Myers Squibb Company HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Bristol-Myers Squibb Company HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bristol-Myers Squibb Company Recent Developments
11.6 Janssen Pharmaceuticals, Inc.
11.6.1 Janssen Pharmaceuticals, Inc. Company Information
11.6.2 Janssen Pharmaceuticals, Inc. Overview
11.6.3 Janssen Pharmaceuticals, Inc. HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Janssen Pharmaceuticals, Inc. HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Janssen Pharmaceuticals, Inc. Recent Developments
11.7 Boehringer Ingelheim International GmbH
11.7.1 Boehringer Ingelheim International GmbH Company Information
11.7.2 Boehringer Ingelheim International GmbH Overview
11.7.3 Boehringer Ingelheim International GmbH HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Boehringer Ingelheim International GmbH HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Boehringer Ingelheim International GmbH Recent Developments
11.8 AbbVie Inc.
11.8.1 AbbVie Inc. Company Information
11.8.2 AbbVie Inc. Overview
11.8.3 AbbVie Inc. HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 AbbVie Inc. HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 AbbVie Inc. Recent Developments
11.9 Genentech, Inc.
11.9.1 Genentech, Inc. Company Information
11.9.2 Genentech, Inc. Overview
11.9.3 Genentech, Inc. HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Genentech, Inc. HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Genentech, Inc. Recent Developments
11.10 Mylan N.V.
11.10.1 Mylan N.V. Company Information
11.10.2 Mylan N.V. Overview
11.10.3 Mylan N.V. HIV Therapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Mylan N.V. HIV Therapy Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Mylan N.V. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 HIV Therapy Industry Chain Analysis
12.2 HIV Therapy Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 HIV Therapy Production Mode & Process
12.4 HIV Therapy Sales and Marketing
12.4.1 HIV Therapy Sales Channels
12.4.2 HIV Therapy Distributors
12.5 HIV Therapy Customers
13 Market Dynamics
13.1 HIV Therapy Industry Trends
13.2 HIV Therapy Market Drivers
13.3 HIV Therapy Market Challenges
13.4 HIV Therapy Market Restraints
14 Key Findings in The Global HIV Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
*If Applicable.